相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase III Clinical Trials That Integrate Treatment and Biomarker Evaluation
Boris Freidlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis
Claire L. Vale et al.
CANCER TREATMENT REVIEWS (2012)
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
Robert Pirker et al.
LANCET ONCOLOGY (2012)
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
Hai T. Tran et al.
LANCET ONCOLOGY (2012)
The Influence of Low and Moderate Carotid Stenosis on Neurophysiologic Status of Patients Undergoing on-pump Coronary Artery Bypass Grafting
Olga Trubnikova et al.
Frontiers in Neurology (2012)
Maintenance Therapy Comes of Age for Non-Small-Cell Lung Cancer, but at What Cost?
Frances A. Shepherd
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer
Wolfram Brugger et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Biospecimen Reporting for Improved Study Quality (BRISQ)
Helen M. Moore et al.
JOURNAL OF PROTEOME RESEARCH (2011)
Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?
Michael Weller et al.
FUTURE ONCOLOGY (2010)
Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non-Small-Cell Lung Cancer
Shirin Khambata-Ford et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Clinical Trials With Biomarkers: Design Issues
Boris Freidlin et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment
Sheila E. Taube et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker et al.
LANCET (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Biomarker-adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect
Wenyu Jiang et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer
N. Lynn Henry et al.
ONCOLOGIST (2006)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
分享论文
